Effect of ionophore A23187 upon membrane function and ion movement in human and toad erythrocytes.
Addition of 0.1-0.3 micronM A23187, a divalent cation ionophore, to human erythrocytes suspended in a 1.0 mM 45Ca2+ -containing buffer results in a small (approximately two fold) increase in [Ca2+]i, a significant decrease in osmotic fragility, and a decrease in intracellular K+ (100 mmoles/liter of cells to 70 mmoles/liter cells) without significant alteration of intracellular [Na+]. This decrease in [K+]i is associated with a significant decrease in packed cell volume and correlates directly with the observed alteration is osmotic fragility. Increasing extracellular K+ to 125 mM prevents the A23187-induced changes in osmotic fragility, K+ content and cell volume, but does not prevent the ionophore-induced uptake of 45Ca2+. Addition of 0.1-0.3 micronM A23187 to toad erythrocytes leads to an increase in 45Ca2+ uptake comparable to that observed in human erythrocytes, but does not alter osmotic fragility, cell volume or K+ content. Higher concentrations of ionophore (3.0-10.0 micronM) cause a 30- to 50-fold increase in 45Ca2+ uptake and concomitant change in K+ content, cell volume and osmotic fragility. These changes in cell properties can be prevented by increasing extracellular [K+] to 90 mM. The difference in sensitivity of the two cell types to A23187 is attributed to the presence of additional intracellular calcium  pools within toad erythrocytes that prevent an increase in cytoplasmic Ca2+ until Ca2+ uptake is increased substantially at the higher concentrations of A23187.
D000255:Adenosine Triphosphate / Q000097:blood; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002021:Buffers; D002024:Bufo marinus; D000001:Calcimycin / Q000097:blood / Q000494:pharmacology*; D002118:Calcium / Q000097:blood* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000378:metabolism*; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D008274:Magnesium / Q000494:pharmacology; D009996:Osmotic Fragility / Q000187:drug effects; D011188:Potassium / Q000097:blood* / Q000494:pharmacology; D012964:Sodium / Q000097:blood; D013997:Time Factors
D000900:Anti-Bacterial Agents; D002021:Buffers; D000001:Calcimycin; D000255:Adenosine Triphosphate; D012964:Sodium; D008274:Magnesium; D011188:Potassium; D002118:Calcium